Earnings summaries and quarterly performance for GE HealthCare Technologies.
Executive leadership at GE HealthCare Technologies.
Peter J. Arduini
Detailed
President and Chief Executive Officer
CEO
BL
Betty Larson
Detailed
Chief People Officer
FJ
Frank Jimenez
Detailed
General Counsel and Corporate Secretary
JS
James Saccaro
Detailed
Vice President and Chief Financial Officer
KS
Kenneth Stacherski
Detailed
Chief Global Supply Chain and Service Officer
KO
Kevin O’Neill
Detailed
CEO, Pharmaceutical Diagnostics
RR
Roland Rott
Detailed
President and CEO, Imaging
TK
Taha Kass-Hout
Detailed
Chief Science and Technology Officer
TW
Thomas Westrick
Detailed
CEO, Patient Care Solutions
Board of directors at GE HealthCare Technologies.
AT
Anne T. Madden
Detailed
Director
CL
Catherine Lesjak
Detailed
Director
HL
H. Lawrence Culp, Jr.
Detailed
Chair of the Board
PL
Phoebe L. Yang
Detailed
Director
RL
Risa Lavizzo-Mourey
Detailed
Lead Independent Director
RF
Rodney F. Hochman
Detailed
Director
TM
Tomislav Mihaljevic
Detailed
Director
WJ
William J. Stromberg
Detailed
Director
Research analysts who have asked questions during GE HealthCare Technologies earnings calls.
DR
David Roman
Goldman Sachs Group Inc.
8 questions for GEHC
Also covers: ABT, BAX, BDX +18 more
Joanne Wuensch
Citigroup Inc.
8 questions for GEHC
Also covers: ABT, BAX, BDX +18 more
Vijay Kumar
Evercore ISI
8 questions for GEHC
Also covers: A, ABT, AVTR +21 more
AP
Anthony Petrone
Mizuho Group
6 questions for GEHC
Also covers: ADMA, ALC, BSX +22 more
RM
Robert Marcus
JPMorgan Chase & Co.
6 questions for GEHC
Also covers: ABT, BAX, BDX +21 more
LB
Larry Biegelsen
Wells Fargo & Company
4 questions for GEHC
Also covers: ABT, ALC, AXNX +24 more
LB
Lawrence Biegelsen
Wells Fargo
3 questions for GEHC
Also covers: ABT, ALC, BAX +16 more
MT
Matthew Taylor
Jefferies
3 questions for GEHC
Also covers: ALUR, BDX, BSX +19 more
Ryan Zimmerman
BTIG
3 questions for GEHC
Also covers: ALC, GKOS, GMED +23 more
CB
Craig Bijou
Bank of America Securities
2 questions for GEHC
Also covers: BLCO, COO, FNA +9 more
Matt Miksic
Barclays Investment Bank
2 questions for GEHC
Also covers: ABT, ATEC, BAX +14 more
Patrick Wood
Morgan Stanley
2 questions for GEHC
Also covers: ALC, BDX, BLCO +17 more
Travis Steed
Bank of America
2 questions for GEHC
Also covers: ABT, AXNX, BAX +20 more
AG
Allen Gong
JPMorgan Chase & Co.
1 question for GEHC
Also covers: ESTA, GKOS, INGN +3 more
Jason Bednar
Piper Sandler Companies
1 question for GEHC
Also covers: ALGN, COO, EDAP +15 more
MT
Matt Taylor
Jefferies & Company Inc.
1 question for GEHC
Also covers: ABT, BAX, BIO +12 more
NT
Navann Ty Dietschi
BNP Paribas
1 question for GEHC
Also covers: COO, ELAN, EOLS +6 more
RW
Rick Wise
Stifel Financial Corp
1 question for GEHC
Also covers: BDX, BSX, ISRG +8 more
RM
Robbie Marcus
JPMorgan Chase & Co.
1 question for GEHC
Also covers: ABT, BAX, BDX +10 more
VC
Vik Chopra
Wells Fargo & Company
1 question for GEHC
Also covers: ALGN, ATEC, CNMD +8 more
Recent press releases and 8-K filings for GEHC.
EXACT Therapeutics: GE Medical Holding Exercises Warrants
GEHC
Convertible Preferred Issuance
- GE Medical Holding AB, a subsidiary of GE HealthCare Technologies, will exercise 26,973,169 warrants in EXACT Therapeutics.
- The warrant exercise will generate NOK 33 million in gross proceeds for EXACT Therapeutics.
- These warrants were issued in the December 2024 private placement and became exercisable after a positive safety read-out from the phase 2 ENACT pancreatic cancer trial on 27 January 2026.
- Remaining warrant holders may exercise their warrants until 26 February 2026.
1 day ago
GE HealthCare reports record FY25 revenue
GEHC
Earnings
Guidance Update
- GE HealthCare delivered record FY2025 revenue of $20.6 billion and Q4 revenue of $5.7 billion, led by Imaging and advanced visualization growth.
- The company achieved full-year adjusted EPS of $4.59 and Q4 adjusted EPS of $1.44, overcoming a $0.43 EPS tariff headwind in 2025.
- Segment revenues were $9.25 billion for Imaging (EBIT down 12.5%), $5.35 billion for AVS (EBIT up 0.7%), and $2.9 billion for Pharmaceutical Diagnostics (EBIT up 10%).
- Management set FY26 guidance for adjusted EPS of $4.95–$5.15 and 3–4% organic revenue growth, and expects a reduced tariff impact next year.
- Q4 ended with a record $21.8 billion backlog, a 1.06x book-to-bill, and $916 million in free cash flow.
2 days ago
GE HealthCare reports Q4 2025 results
GEHC
Earnings
Guidance Update
M&A
- Q4 revenue of $5.7 billion, organic growth 4.8%, adjusted EPS $1.44, free cash flow $916 million; record backlog of $21.8 billion and book-to-bill of 1.06x
- Full-year 2025 revenue of $20.6 billion (+3.5% organic) with adjusted EPS $4.59 and adjusted EBIT margin 15.3%
- 2026 guidance: organic revenue growth 3%–4%, adjusted EPS $4.95–$5.15 (+8%–12%), adjusted EBIT margin 15.8%–16.1%, and free cash flow of $1.7 billion
- Announced planned acquisition of Intelerad, expected to add ~$270 million in first-year revenue (low-double-digit growth) with >30% adjusted EBITDA
- Innovation pipeline remains strong with a three-year vitality rate of 55% and new launches including Omni total body PET, next-gen SPECT, Photonova Spectra photon-counting CT, SIGNA MR with Freelium, Vivid Pioneer ultrasound, and Flyrcado perfusion imaging
2 days ago
GE HealthCare reports Q4 2025 results
GEHC
Earnings
Guidance Update
- Revenue of $5.7 B with 4.8% organic growth and 1.06× book-to-bill, driven by strength in U.S. and EMEA and record backlog.
- Adjusted EPS of $1.44, down 0.7% YoY, excluding a $0.17 tariff impact.
- Free cash flow of $916 M, up $105 M YoY, despite a $90 M tariff headwind.
- 2026 outlook: organic revenue growth 3.0%–4.0%, adjusted EBIT margin 15.8%–16.1%, adjusted EPS $4.95–$5.15, and FCF ~ $1.7 B.
2 days ago
GE HealthCare reports Q4 2025 results
GEHC
Earnings
Guidance Update
M&A
- Delivered $5.7 billion in Q4 revenue with 4.8% organic growth; adjusted EBIT margin was 16.7%, adjusted EPS $1.44, and free cash flow $916 million.
- Full-year 2025 revenue of $20.6 billion (+3.5% organic), record backlog, adjusted EPS $4.59, and free cash flow $1.5 billion, despite a $245 million tariff impact.
- 2026 guidance: 3–4% organic revenue growth, adjusted EBIT margin 15.8–16.1%, adjusted EPS $4.95–$5.15, and free cash flow of $1.7 billion.
- Announced acquisition of Intelerad, expected to contribute $270 million in first-year revenue and >30% adjusted EBITDA.
- Heartbeat business system rollout drove a 25% monthly improvement in past-due backlog, boosting sales and cash conversion in 2025.
2 days ago
GE HealthCare reports Q4 2025 results
GEHC
Earnings
Guidance Update
M&A
- Delivered $5.7 billion in Q4 revenue, up 4.8% organically; adjusted EPS of $1.44 (–0.7%), rising 11% ex-tariffs; free cash flow of $916 million (+$105 million).
- Achieved full-year 2025 revenue of $20.6 billion (+3.5% organic) with adjusted EPS of $4.59 (+2.2%; +12% ex-tariffs); tariffs dragged EPS by $0.43.
- Exited Q4 with record backlog of $21.8 billion (+$2.0 billion YoY), a book-to-bill of 1.06×, and 2% orders growth.
- Advanced strategy with planned acquisition of Intelerad (first-year revenues ~$270 million, >30% adjusted EBITDA) and 55% of 2025 revenues from new products.
- 2026 outlook: organic revenue growth of 3–4%, a cautious China assumption, and targeted EPS expansion (~$0.45 at midpoint) driven by volume, cost productivity, and strategic investments.
2 days ago
GE HealthCare reports Q4 2025 results
GEHC
Earnings
Guidance Update
M&A
- Fourth quarter 2025 revenues of $5.7 billion, up 7.1% YoY (organic +4.8%), net income margin 10.3%, adjusted EPS $1.44, and free cash flow $916 million.
- Full-year 2025 revenues of $20.6 billion, up 4.8% YoY (organic +3.5%), diluted EPS $4.55, adjusted EPS $4.59, and free cash flow $1.5 billion.
- In April 2025, the board authorized a $1.0 billion share repurchase program, of which $200 million was executed in 2025.
- Announced planned $2.3 billion acquisition of Intelerad, expected to close in H1 2026.
- 2026 guidance includes organic revenue growth of 3.0%–4.0%, adjusted EBIT margin 15.8%–16.1%, adjusted EPS $4.95–5.15, and free cash flow of approximately $1.7 billion.
3 days ago
GE HealthCare reports Q4 and full year 2025 results
GEHC
Earnings
Guidance Update
- Q4 revenues were $5.7 billion, up 7.1% year-over-year (organic +4.8%).
- Q4 EPS: diluted EPS of $1.29 and adjusted EPS of $1.44; net income margin 10.3%, adjusted EBIT margin 16.7%.
- Full-year 2025: revenues of $20.6 billion (+4.8%, organic +3.5%), diluted EPS $4.55, adjusted EPS $4.59, operating cash flow $2.0 billion, free cash flow $1.5 billion.
- 2026 guidance: organic revenue growth 3.0%–4.0%, adjusted EPS $4.95–$5.15, free cash flow ≈ $1.7 billion.
3 days ago
GE HealthCare presents at 44th Annual J.P. Morgan Healthcare Conference
GEHC
Product Launch
Guidance Update
M&A
- GE HealthCare reiterated its three strategic pillars—precision care, growth acceleration, business optimization—and its 2026–2028 midterm financial framework targeting mid-single-digit revenue growth, 20 %+ adjusted EBIT margin, high single-digit EPS growth, and 90 %+ free cash flow.
- The company showcased nine major product launches slated for 2026, including the Omni total-body PET, Photonova Spectra photon-counting CT, StarGuide GX dual-energy nuclear system, new MR platforms, Vivid Pioneer ultrasound, and Allia IGS cath lab suite.
- It leads MedTech in AI with 115 FDA-authorized algorithms, plans to commercialize multimodal AI via its CareIntellect platform, and announced the acquisition of Intelerad to build a cloud-first, AI-orchestration PACS system.
- In radiopharmaceutical diagnostics, GE HealthCare launched Flyrcado for myocardial perfusion imaging, expects over $500 million in sales by 2028, and sees a potential $1 billion market with 25 % PET MPI penetration.
Jan 13, 2026, 6:30 PM
GE HealthCare outlines midterm growth framework and product pipeline at JPMorgan Healthcare Conference
GEHC
Guidance Update
Product Launch
M&A
- At the 44th Annual J.P. Morgan Healthcare Conference, CEO Peter Arduini presented a 2026–2028 midterm framework targeting mid-single-digit revenue growth, 18–20% adjusted EBIT, high-single-digit to low-double-digit EPS, and 90%+ free cash flow
- Unveiled nine major product launches slated for 2026, including the Omni total-body PET system, Photonova Spectra photon-counting CT, StarGuide GX SPECT, Vivid Pioneer ultrasound, Allia Moveo cath lab, and MR platform enhancements
- Emphasized leadership in AI with 115 FDA authorizations—the most in medtech—and plans to monetize AI via the new CareIntellect cloud deployment platform
- Announced agreement to acquire Intelerad in H1 2026, integrating a cloud-first, AI-enabled PACS to bolster recurring software revenue
Jan 13, 2026, 6:30 PM
Quarterly earnings call transcripts for GE HealthCare Technologies.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more